Figure 5.
PFS in patients with ≥1 extended belamaf dose delay of ≥12 weeks. (A-B) Post hoc analysis evaluating patients who had ≥1 belamaf dose delay of ≥12 weeks in (A) DREAMM-7 (BVd, n = 146) and (B) DREAMM-8 (BPd, n = 98). NR, not reached.
PFS in patients with ≥1 extended belamaf dose delay of ≥12 weeks. (A-B) Post hoc analysis evaluating patients who had ≥1 belamaf dose delay of ≥12 weeks in (A) DREAMM-7 (BVd, n = 146) and (B) DREAMM-8 (BPd, n = 98). NR, not reached.
